Getting to transplant in Hodgkin lymphoma: BVB

Leo I. Gordon

doi:10.1182/blood-2018-05-848366

Getting to transplant in Hodgkin lymphoma: BVB

Leo I. Gordon

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

In this issue of Blood, LaCasce et al present data on the incorporation of brentuximab vedotin (BV) with bendamustine (BVB) in patients with recurrent/refractory classical Hodgkin lymphoma (HL) that might be practice-changing.¹

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Blood
Volume	132
Issue number	1
DOIs	https://doi.org/10.1182/blood-2018-05-848366
State	Published - Jul 5 2018

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2018-05-848366

Cite this

@article{46b461ef9cb143629ce51376f60b9268,

title = "Getting to transplant in Hodgkin lymphoma: BVB",

abstract = "In this issue of Blood, LaCasce et al present data on the incorporation of brentuximab vedotin (BV) with bendamustine (BVB) in patients with recurrent/refractory classical Hodgkin lymphoma (HL) that might be practice-changing.1",

author = "Gordon, {Leo I.}",

note = "Publisher Copyright: {\textcopyright} 2018 by The American Society of Hematology.",

year = "2018",

month = jul,

day = "5",

doi = "10.1182/blood-2018-05-848366",

language = "English (US)",

volume = "132",

pages = "1--3",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Getting to transplant in Hodgkin lymphoma

T2 - BVB

AU - Gordon, Leo I.

PY - 2018/7/5

Y1 - 2018/7/5

N2 - In this issue of Blood, LaCasce et al present data on the incorporation of brentuximab vedotin (BV) with bendamustine (BVB) in patients with recurrent/refractory classical Hodgkin lymphoma (HL) that might be practice-changing.1

AB - In this issue of Blood, LaCasce et al present data on the incorporation of brentuximab vedotin (BV) with bendamustine (BVB) in patients with recurrent/refractory classical Hodgkin lymphoma (HL) that might be practice-changing.1

UR - http://www.scopus.com/inward/record.url?scp=85049597896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049597896&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-05-848366

DO - 10.1182/blood-2018-05-848366

M3 - Review article

C2 - 29976776

AN - SCOPUS:85049597896

SN - 0006-4971

VL - 132

SP - 1

EP - 3

JO - Blood

JF - Blood

IS - 1

ER -

Getting to transplant in Hodgkin lymphoma: BVB

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this